Review: 'Through the Shadowlands’ describes Julie Rehmeyer's ME/CFS Odyssey
I should note at the outset that this review is based on an audio version of the galleys and the epilogue from the finished work. Julie Rehmeyer sent me the final version as a PDF, but for some reason my text to voice software (Kurzweil) had issues with it. I understand that it is...
Discuss the article on the Forums.

Overview of the Drug Development Landscape

Discussion in 'General ME/CFS News' started by lnester7, Mar 26, 2013.

  1. lnester7

    lnester7 Seven

    Messages:
    2,444
    Likes:
    3,537
    USA
    http://www.research1st.com/2013/03/18/upcoming-webinar-1/

    Date/Time: March 28, 2013 at 1:00 p.m. EDT
    Speaker: Kristin Schneeman, Program Director, FasterCures Host: Kim McCleary, CEO, The CFIDS Association of America
    Registration: http://bit.ly/spring-series-1

    In the first program of our Spring 2013 Webinar Series, we welcome Kristin Schneeman, program director for FasterCures, as our guest speaker. Kristin will outline the process to translate scientific discoveries into accessible medical solutions. She will define the major components of the research and development (R&D) cycle as a basis for helping community members understand the landscape for drug development. She will contrast it with the landscape for basic research, an area that is more familiar to most patient advocates and community members.
     

See more popular forum discussions.

Share This Page